Prevention of cervical cancer: journey to develop the first human papillomavirus virus-like particle vaccine and the next generation vaccine
Authors:
- 1 June 2016
- journal article
- review article
- Published by Elsevier in Current Opinion in Chemical Biology
- Vol. 32, 34-47
Abstract
No abstract availableKeywords
Funding Information
- Merck Research Laboratories
This publication has 76 references indexed in Scilit:
- Efficacy of Human Papillomavirus 16 and 18 (HPV-16/18) AS04-Adjuvanted Vaccine against Cervical Infection and Precancer in Young Women: Final Event-Driven Analysis of the Randomized, Double-Blind PATRICIA TrialClinical and Vaccine Immunology, 2015
- Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional studyThe Lancet Infectious Diseases, 2014
- Global Burden of Human Papillomavirus and Related DiseasesVaccine, 2012
- Human Papillomavirus and Cervical Cancer in Australasia and Oceania: Risk-factors, Epidemiology and PreventionVaccine, 2008
- Human papillomavirus and cervical cancerThe Lancet, 2007
- Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical CancerNew England Journal of Medicine, 2003
- Cervical cancer risk: is there a genetic component?Molecular Medicine Today, 2000
- Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic.Proceedings of the National Academy of Sciences, 1992
- Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particlesVirology, 1991
- Partial characterization of viral DNA from human genital warts (condylomata acuminata)International Journal of Cancer, 1980